Prostaglandin-endoperoxide synthase 2 (COX-2) and inflammatory cytokines (COX-2 and cytokines)

Prostaglandin-endoperoxide synthase 2 (COX-2) is an inducible enzyme that catalyzes the conversion of arachidonic acid to Prostaglandin H2, a precursor for various pro-inflammatory prostanoids (UniProt: P35354). Inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), are pleiotropic signaling proteins that regulate the magnitude and duration of the immune response (PubMed: 27648125). In pathological states, COX-2 and these cytokines form a self-amplifying loop where cytokines induce COX-2 expression, and prostaglandin products can further modulate cytokine production, leading to chronic inflammation and tissue damage (StatPearls: NBK549778). This axis is a primary therapeutic target in conditions such as rheumatoid arthritis, osteoarthritis, and certain cancers, where over-expression drives disease progression (NIH: PMC3154070). Pharmacological strategies include selective COX-2 inhibitors (coxibs) to reduce pain and swelling, and biologic agents like monoclonal antibodies to neutralize specific cytokines (PubChem: CID 2662). However, long-term inhibition of these pathways is associated with significant safety concerns, including increased cardiovascular risk for COX-2 inhibitors and heightened susceptibility to opportunistic infections for cytokine-targeting therapies (PubMed: 15128331).

Other names

PTGS2Cyclooxygenase-2COX2Prostaglandin G/H synthase 2TNF-alphaIL-1IL-6Pro-inflammatory mediators

Inhibition of the cyclooxygenase activity of PTGS2 to prevent prostaglandin synthesis; Neutralization of circulating cytokines or blockade of their respective receptors to inhibit downstream inflammatory signaling.